Biological Therapies for Rheumatoid Arthritis: Progress to Date

被引：0
作者：
Gaurav Malviya
Simonetta Salemi
Bruno Laganà
Andrea Picchianti Diamanti
Raffaele D’Amelio
Alberto Signore
机构：
[1] University Medical Centre Groningen,Department of Nuclear Medicine and Molecular Imaging
[2] University of Groningen,Nuclear Medicine Department, Faculty of Medicine and Psychology
[3] “Sapienza” University of Rome,Clinical Immunology and Rheumatology Unit, Faculty of Medicine and Psychology
[4] St. Andrea Hospital,undefined
[5] “Sapienza” University of Rome,undefined
来源：
BioDrugs | 2013年 / 27卷
关键词：
Rheumatoid Arthritis; Infliximab; Rheumatoid Arthritis Patient; Etanercept; Adalimumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Biologic drugs for the management of rheumatoid arthritis (RA) have revolutionized the therapeutic armamentarium with the development of several novel monoclonal antibodies, which include murine, chimeric, humanized, fully human antibodies and fusion proteins. These biologics bind to their targets with high affinity and specificity. Since 1998, nine different biologics have been approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of RA, and several others are in different stages of clinical trials. This field is in continuous evolution and new biologics are tested every year. Therefore a precise analysis is required in order to have a detailed and updated state of the art of this field. In this review, our main aim is to analyse all available biological therapies that are FDA and EMA approved for the treatment of RA and also those that are in clinical trials for the management of RA patients.
引用
收藏
页码：329 / 345
页数：16
相关论文
共 651 条
[91]  
Dear PH(1992)Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule Science 257 792-363
[92]  
Foote J(1996)Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases N Engl J Med 335 1369-1593
[93]  
Neuberger MS(2006)Role of abatacept in the management of rheumatoid arthritis Clin Therap 28 11-1186
[94]  
Winter G(2006)Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life J Rheumatol 33 681-259
[95]  
Holmes MA(2006)Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study Arthritis Rheum 54 2807-1450
[96]  
Buss TN(2006)Biologics targeted at TNF: design, production and challenges Reumatismo 58 94-1074
[97]  
Foote J(2001)Anti-TNF-α therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 19 163-382
[98]  
Rajagopalan K(2004)Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicentre, randomized, double blind placebo controlled trial Arthritis Rheum 50 353-472
[99]  
Pavlinkova G(2000)A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis N Engl J Med 343 1586-3265
[100]  
Levy S(2004)Etanercept: a clinical review of current and emerging indications Expert Opin Pharmacother 5 1175-1756
567891011121314